On June 22, 2020, the U.S. Food and Drug Administration (FDA) announced it has approved selinexor (XPOVIO, Karyopharm Therapeutics, Inc.), a single-agent oral tablet, for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.
This is the first oral agent approved for the treatment of DLBCL.
“The approval of selinexor offers patients with relapsed or refractory diffuse large B-cell lymphoma a new treatment option and new hope for the future,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “New medicines can transform the way healthcare providers approach this type of blood cancer and we commend those who contribute to accelerating research for the benefit of patients.”
For more information on the FDA approval of selinexor (XPOVIO), visit the FDA’s website or lymphoma.org/DLBCLFDAUpdates.
